Sai Parenteral's IPO

The company has delivered strong financial growth over the last two years. Revenue from operations increased to ₹163.10 crore in FY25 from ₹96.79 crore in FY23, while net profit rose sharply to ₹14.45 crore from ₹4.37 crore, which shows the business is scaling up and running more efficiently.

Its contract manufacturing business is growing very quickly, with an annual growth rate of 80.46%. Revenue from this segment jumped to ₹31.24 crore in FY25 from just ₹5.31 crore in FY23, which suggests that both Indian and overseas pharma clients are placing more trust in the company.

The company has also made a smart global move by acquiring a 74.64% stake in Noumed Pharmaceuticals in Australia. This gives it access to more than 451 approved product dossiers, which are drug approval files, along with long-term supply contracts that can improve export opportunities and make future revenue more predictable.

One good sign is that the business is no longer depending too heavily on injectables alone. It has expanded well into tablets, liquid medicines, and ointments, and now has 302 marketed products, with tablets contributing 36.23% of FY25 revenue and liquid orals adding 9.22%, showing a more balanced product mix.

The company is also generating better returns from the money invested in the business. Its Return on Capital Employed, or ROCE, which simply tells us how efficiently a company uses its capital to earn operating profit, improved to 28.92% in FY25 from 21.04% in FY23.

On the manufacturing side, the company operates five factories with a combined annual capacity of 1,160 million units. Some of these facilities hold important global approvals like TGA-Australia and WHO-GMP, which help the company supply medicines in tightly regulated international markets.

One concern is that the company has had trouble turning its core business into actual cash. It reported a negative operating cash flow of ₹66.01 crore in the first half of FY26 and ₹29.76 crore in FY24, mainly because a lot of money is getting tied up in working capital, which means inventory and customer payments that have not come in yet.

The business also depends quite a lot on a small set of customers. In FY25, its top 10 customers contributed 69.47% of branded generic formulation revenue, so if even a few major buyers reduce orders or move elsewhere, sales could take a noticeable hit.

To complete the planned factory upgrades needed for entry into European markets, the company will have to temporarily suspend operations at Units I and II for around six months. Management has estimated that this disruption could lead to a potential revenue loss of about ₹42.20 crore, which is not a small number.

Even though the company is planning more expansion, some of its current facilities are still not being used fully. In FY25, Unit IV operated at only 30.48% capacity and Unit III at 49.40%, which basically means part of the capital is sitting in underused machinery instead of generating better returns.

On the supplier side, too, there is a concentration risk. The company buys most of its raw materials from a limited group of vendors without long-term supply contracts, which leaves it exposed to sudden price increases or supply disruptions. In FY25, just 10 suppliers accounted for 82.70%, or ₹77.61 crore, of total purchases.

This is also a business that operates under close regulatory watch, and that brings its own set of risks. The company has faced blacklisting orders linked to alleged sub-standard products, and its subsidiary Revat was temporarily told to stop manufacturing in May 2024 because of compliance issues, which can hurt both reputation and business continuity.

Another weak spot is that all five manufacturing plants are located close to each other in Telangana and Andhra Pradesh. So if that region faces any local disruption, whether it is political trouble, a natural event, or even basic power and water issues, operations across the company could be affected at the same time.